Transform brain health through the integration of precision medicine into psychiatry and neurology.

PI

• Dr. Tal Patalon, MD, LLB, MBA (Head of KSM Maccabi Research and Innovation Center)

‍DESCRIPTION

NeuroKaire (formerly Genetika+) is developing a data-driven decision support system to help physicians personalize treatment choices for patients with major depressive disorder (MDD). This retrospective study aims to develop and validate a machine learning model for this system using the Maccabi dataset, which contains real-world data from a large and diverse patient population. The primary objective is to create a classification model that predicts treatment response to antidepressants based on individual patient characteristics. Secondary objectives include analyzing care pathways, prescription patterns, and healthcare utilization to identify potential predictors of treatment response.

‍

PARTICIPANTS

The study will involve anonymized electronic medical records of 90,000 patients with depression and 10,000 controls.

PI

• PI - Prof. Jonathan Rabinowitz, PhD (Elie Wiesel Professor, Bar-Ilan University)
• Sarah F. Feldman, MD, MPH, MSc

‍DESCRIPTION

Developing a Comprehensive Prediction Model for Antidepressant Response in MDD

This study aims to develop a machine learning-based classification model to predict antidepressant treatment response in patients with major depressive disorder (MDD). The model will incorporate a wide range of patient data, including demographics, clinical assessments, medical conditions, clinical rating scales, questionnaires, medical care information, behavioral measures, neurocognitive testing, and genomic, genetic, and proteomic profiles. The performance of the model will be evaluated using different response definitions, including the MADRS and QIDS scores. Additionally, the study will investigate potential biomarkers associated with treatment response, treatment resistance, and optimal dosage. Finally, correlations between clinical and molecular features will be explored to gain further insights into the underlying mechanisms of MDD and treatment response.

‍

PARTICIPANTS

CAN BIND 1st phase Cohort - 309 patients (206 MDD and 103 control).